Search

Your search keyword '"Belloso W"' showing total 89 results

Search Constraints

Start Over You searched for: Author "Belloso W" Remove constraint Author: "Belloso W"
89 results on '"Belloso W"'

Search Results

1. Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study

2. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study

4. Controller Therapy Evaluation Among COPD Patients from Hospital Italiano, Argentina

5. Characteristics of COPD Patients Before First Controller Therapy from Hospital Italiano, Argentina

7. Prevalence of Asthma and Severe Asthma in Patients Affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina

8. Characterization of Severe Asthma Patients Affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina

10. Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study

11. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study

12. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

13. Artificial Pancreas: First Clinical Trials in Argentina

14. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

15. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

16. Individualized Antiretroviral Therapy. Impact of pharmacogenetic and therapeutic drug monitoring in the safety and efficacy of first line antirretroviral therapy in patients with HIV infection. Preliminary report

19. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.

20. Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study.

21. Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study

22. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

23. Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART

24. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study

25. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

26. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection

28. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial

29. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons

30. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals

31. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

32. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

33. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count >= 300 cells/mu L who were assigned to 7.5 MIU interleukin

36. A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial

40. Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons

41. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

42. Renal Functional Reserve in Naïve HIV Patients.

43. Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma.

44. Acute Kidney Injury Pharmacokinetic Changes and Its Impact on Drug Prescription.

45. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.

46. Prevalence of thymidylate synthase gene 5'-untranslated region variants in an Argentinean sample.

47. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.

48. Prevalence of CYP2B6 polymorphisms in Argentinians: the role of genetic testing.

49. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

Catalog

Books, media, physical & digital resources